PLMA_1170x120_7-2-21

Paul Fonteyne

Boehringer Ingelheim names Baiker as new U.S. president

Boehringer Ingelheim names Baiker as new U.S. president

RIDGEFIELD, Conn.– Boehringer Ingelheim announced that its U.S. president and chief executive officer Paul Fonteyne will retire and Wolfgang Baiker has been appointed to succeed him, effective March 1. The position will be based at the pharmaceutical company’s U.S. headquarters in Ridgefield. “I am thrilled to return to the U.S. to lead this organization and

Jardiance approved to cut cardiovascular death risk

Jardiance approved to cut cardiovascular death risk

RIDGEFIELD, Conn., and INDIANAPOLIS — Jardiance tablets, marketed by Boehringer Ingelheim and Eli Lilly and Co., have been approved by the Food and Drug Administration to cut the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. BI and Lilly said the FDA clearance makes Jardiance (empagliflozin) the first type

Lilly, BI cleared to market Basaglar long-acting insulin

Lilly, BI cleared to market Basaglar long-acting insulin

INDIANAPOLIS and RIDGEFIELD, Conn. — Eli Lilly and Co. and Boehringer Ingelheim Pharmaceuticals Inc. have received approval for Basaglar long-acting insulin (insulin glargine injection, 100 units/ml) in the United States. The companies said Basaglar has an identical amino acid sequence to Lantus, another U-100 insulin glargine, and is delivered via the prefilled Basaglar KwikPen. Basaglar

FDA approves Boehringer Ingelheim, Eli Lilly’s Synjardy

FDA approves Boehringer Ingelheim, Eli Lilly’s Synjardy

RIDGEFIELD, Conn., and INDIANAPOLIS — Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Co. have received approval from the Food and Drug Administration for Synjardy tablets, a medication for type 2 diabetes. The companies said Thursday that Synjardy (empagliflozin and metformin hydrochloride) marks their third product containing empagliflozin to be approved by the FDA, following